NO20060502L - Forbindelser for behandling av metabolske forstyrrelser - Google Patents

Forbindelser for behandling av metabolske forstyrrelser

Info

Publication number: NO20060502L
Authority: NO; Norway
Prior art keywords: carbon atoms; hydrogen; alkyl; ring; methyl
Prior art date: 2003-08-20

Application number

NO20060502A

Other languages

English (en)

Norwegian (no)

Inventor

Shalini Sharma

Kirvin L Hodge

Reid W Von Borstel

Original Assignee

Wellstat Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-20

Filing date

2006-01-31

Publication date

2006-05-03

2006-01-31 Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp

2006-05-03 Publication of NO20060502L publication Critical patent/NO20060502L/no

Links

150000001875 compounds Chemical class 0.000 title abstract 3
208000030159 metabolic disease Diseases 0.000 title abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 9
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000010706 fatty liver disease Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
-1 perfluoromethoxy Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20060502A 2003-08-20 2006-01-31 Forbindelser for behandling av metabolske forstyrrelser NO20060502L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49653303P	2003-08-20	2003-08-20
PCT/US2004/026561 WO2005018628A1 (en)	2003-08-20	2004-08-16	Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number	Publication Date
NO20060502L true NO20060502L (no)	2006-05-03

Family

ID=34216015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060502A NO20060502L (no)	2003-08-20	2006-01-31	Forbindelser for behandling av metabolske forstyrrelser

Country Status (18)

Country	Link
US (1)	US7906675B2 (pt)
EP (1)	EP1656127B1 (pt)
JP (1)	JP4703563B2 (pt)
KR (1)	KR101069276B1 (pt)
CN (2)	CN101948416A (pt)
AT (1)	ATE502631T1 (pt)
AU (1)	AU2004266673B2 (pt)
BR (1)	BRPI0413758A (pt)
CA (1)	CA2533890A1 (pt)
DE (1)	DE602004031954D1 (pt)
IL (1)	IL173377A (pt)
MX (1)	MXPA06001963A (pt)
NO (1)	NO20060502L (pt)
NZ (1)	NZ545268A (pt)
RU (1)	RU2349584C2 (pt)
UA (1)	UA88772C2 (pt)
WO (1)	WO2005018628A1 (pt)
ZA (1)	ZA200600577B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1750758B (zh) *	2003-02-13	2012-06-20	维尔斯达医疗公司	用于治疗代谢紊乱的化合物
RU2358722C2 (ru) *	2003-04-15	2009-06-20	Веллстат Терапьютикс Корпорейшн	Соединения для лечения метаболических расстройств
JP4837557B2 (ja) *	2003-04-30	2011-12-14	ウェルスタットセラピューティクスコーポレイション	代謝障害の処置のための化合物
CA2602854C (en) *	2005-04-01	2013-05-14	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
UA95613C2 (ru) *	2005-11-09	2011-08-25	Уеллстат Терепьютикс Корпорейшн	Соединения для лечения расстройсв метаболизма
NZ569728A (en) *	2006-01-25	2010-11-26	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders
JP2009528275A (ja) *	2006-01-25	2009-08-06	ウェルスタットセラピューティクスコーポレイション	代謝障害を処置するための化合物
WO2007087505A2 (en) *	2006-01-25	2007-08-02	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
US20090176885A1 (en) *	2006-02-02	2009-07-09	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
EP1983972A4 (en) *	2006-02-13	2012-01-25	Wellstat Therapeutics Corp	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
KR20080098615A (ko) *	2006-02-28	2008-11-11	웰스태트 테러퓨틱스 코포레이션	물질대사 장애의 치료용 화합물
KR20080106455A (ko) *	2006-03-31	2008-12-05	웰스태트 테러퓨틱스 코포레이션	대사장애의 조합치료
CA2651598A1 (en) *	2006-05-18	2007-11-29	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
EP2026659A4 (en) *	2006-06-09	2010-06-30	Wellstat Therapeutics Corp	COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
EP2240024A4 (en) *	2008-01-15	2014-05-21	Wellstat Therapeutics Corp	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CN109096350B (zh) *	2017-09-21	2020-07-28	暨南大学	辣木籽中新的硫醚类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR5035M (pt)	1964-07-28	1967-05-02
CA2283642C (en) *	1997-03-17	2012-05-15	Btg International Limited	Therapeutic compositions
CN101444496B (zh)	2001-06-12	2011-04-13	维尔斯达医疗公司	用于治疗代谢失调的化合物
EP1556085A4 (en)	2002-11-01	2012-08-22	Wellstat Therapeutics Corp	COMPOUNDS FOR THE TREATMENT OF METABOLISM
CN1750758B (zh)	2003-02-13	2012-06-20	维尔斯达医疗公司	用于治疗代谢紊乱的化合物
RU2358722C2 (ru)	2003-04-15	2009-06-20	Веллстат Терапьютикс Корпорейшн	Соединения для лечения метаболических расстройств
US7361686B2 (en)	2003-04-22	2008-04-22	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
JP4837557B2 (ja)	2003-04-30	2011-12-14	ウェルスタットセラピューティクスコーポレイション	代謝障害の処置のための化合物

2004
- 2004-08-16 EP EP04781277A patent/EP1656127B1/en not_active Expired - Lifetime
- 2004-08-16 AT AT04781277T patent/ATE502631T1/de not_active IP Right Cessation
- 2004-08-16 KR KR1020067003221A patent/KR101069276B1/ko not_active Expired - Fee Related
- 2004-08-16 UA UAA200602860A patent/UA88772C2/ru unknown
- 2004-08-16 WO PCT/US2004/026561 patent/WO2005018628A1/en not_active Ceased
- 2004-08-16 CA CA002533890A patent/CA2533890A1/en not_active Abandoned
- 2004-08-16 CN CN2010102937097A patent/CN101948416A/zh active Pending
- 2004-08-16 MX MXPA06001963A patent/MXPA06001963A/es active IP Right Grant
- 2004-08-16 RU RU2006108572/04A patent/RU2349584C2/ru not_active IP Right Cessation
- 2004-08-16 NZ NZ545268A patent/NZ545268A/en unknown
- 2004-08-16 AU AU2004266673A patent/AU2004266673B2/en not_active Ceased
- 2004-08-16 US US10/566,302 patent/US7906675B2/en active Active
- 2004-08-16 DE DE602004031954T patent/DE602004031954D1/de not_active Expired - Lifetime
- 2004-08-16 CN CNA2004800235529A patent/CN1835743A/zh active Pending
- 2004-08-16 BR BRPI0413758-2A patent/BRPI0413758A/pt not_active IP Right Cessation
- 2004-08-16 JP JP2006523964A patent/JP4703563B2/ja not_active Expired - Fee Related
2006
- 2006-01-23 ZA ZA200600577A patent/ZA200600577B/en unknown
- 2006-01-26 IL IL173377A patent/IL173377A/en not_active IP Right Cessation
- 2006-01-31 NO NO20060502A patent/NO20060502L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2007502824A (ja)	2007-02-15
KR20060066730A (ko)	2006-06-16
IL173377A0 (en)	2006-06-11
US7906675B2 (en)	2011-03-15
WO2005018628A1 (en)	2005-03-03
RU2349584C2 (ru)	2009-03-20
MXPA06001963A (es)	2006-05-31
ZA200600577B (en)	2007-01-31
DE602004031954D1 (de)	2011-05-05
EP1656127B1 (en)	2011-03-23
AU2004266673B2 (en)	2010-08-05
AU2004266673A1 (en)	2005-03-03
NZ545268A (en)	2009-05-31
HK1087040A1 (en)	2006-10-06
EP1656127A1 (en)	2006-05-17
CN1835743A (zh)	2006-09-20
CN101948416A (zh)	2011-01-19
BRPI0413758A (pt)	2006-10-31
UA88772C2 (ru)	2009-11-25
CA2533890A1 (en)	2005-03-03
IL173377A (en)	2012-12-31
RU2006108572A (ru)	2006-07-27
ATE502631T1 (de)	2011-04-15
JP4703563B2 (ja)	2011-06-15
KR101069276B1 (ko)	2011-10-04
EP1656127A4 (en)	2009-04-29
US20070282003A1 (en)	2007-12-06

Legal Events

Date	Code	Title	Description
2012-03-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20081821L (no)	2008-07-30	Forbindelser for behandling av metabolske forstyrrelser
NO20053211L (no)	2005-10-20	Forbindelser for behandling av metabolske forstyrrelser.
NO20060502L (no)	2006-05-03	Forbindelser for behandling av metabolske forstyrrelser
CY1111310T1 (el)	2015-08-05	Ενωσεις για την αγωγη μεταβολικων διαταραχων
ATE530066T1 (de)	2011-11-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2007087505A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
WO2007137008A3 (en)	2008-08-28	Compounds for the treatment of metabolic disorders
WO2007095462A3 (en)	2008-05-02	Compounds for the treatment of metabolic disorders
MXPA05011592A (es)	2005-12-15	Compuestos para el tratamiento de trastornos metabolicos.
NO20003399L (no)	2000-08-02	<Alfa>-amionoamidderivater som er nyttige som smertestillende midler
KR960010000A (ko)	1996-04-20	종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물
WO2004093806A3 (en)	2005-04-07	Compounds for the treatment of metabolic disorders
PH12015501098A1 (en)	2015-12-07	Antituberculous composition comprising oxazole compounds
NO20063330L (no)	2006-09-14	Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
EP1868595A4 (en)	2010-06-09	COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
WO2007087504A3 (en)	2007-11-15	Compounds for the treatment of metabolic disorders
NO20074738L (no)	2007-11-08	Aktivator for peroksisom-proliferator som aktiverer reseptor delta
WO2006092507A8 (fr)	2007-11-01	Derives de 1 ,2,4-triazines, leur preparation et leur application en therapeutique humaine
WO2007092729A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders